Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.
Atkins MB, Hodi FS, Thompson JA, McDermott DF, Hwu WJ, Lawrence DP, Dawson NA, Wong DJ, Bhatia S, James M, Jain L, Robey S, Shu X, Homet Moreno B, Perini RF, Choueiri TK, Ribas A. Atkins MB, et al. Among authors: hodi fs. Clin Cancer Res. 2018 Apr 15;24(8):1805-1815. doi: 10.1158/1078-0432.CCR-17-3436. Epub 2018 Jan 22. Clin Cancer Res. 2018. PMID: 29358500 Clinical Trial.
Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.
Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, Ryan BF, Sober AJ, Mihm MC, Tsao H, Langley RG, Cosimi BA, Gadd MA, Tanabe KK, Souba W, Haynes HA, Barnhill R, Osteen R, Haluska FG. Jonasch E, et al. Among authors: hodi fs. Cancer J. 2000 May-Jun;6(3):139-45. Cancer J. 2000. PMID: 10882328 Clinical Trial.
Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.
Linette GP, Zhang D, Hodi FS, Jonasch EP, Longerich S, Stowell CP, Webb IJ, Daley H, Soiffer RJ, Cheung AM, Eapen SG, Fee SV, Rubin KM, Sober AJ, Haluska FG. Linette GP, et al. Among authors: hodi fs. Clin Cancer Res. 2005 Nov 1;11(21):7692-9. doi: 10.1158/1078-0432.CCR-05-1198. Clin Cancer Res. 2005. PMID: 16278389 Clinical Trial.
Cytotoxic T-lymphocyte-associated antigen-4.
Hodi FS. Hodi FS. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5238-42. doi: 10.1158/1078-0432.CCR-07-0813. Clin Cancer Res. 2007. PMID: 17875750 Review.
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E. McDermott DF, et al. Among authors: hodi fs. J Clin Oncol. 2008 May 1;26(13):2178-85. doi: 10.1200/JCO.2007.14.8288. J Clin Oncol. 2008. PMID: 18445842 Clinical Trial.
KIT gene mutations and copy number in melanoma subtypes.
Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F 3rd, Azar S, Rubin BP, Muller S, West R, Heinrich MC, Corless CL. Beadling C, et al. Among authors: hodi fs. Clin Cancer Res. 2008 Nov 1;14(21):6821-8. doi: 10.1158/1078-0432.CCR-08-0575. Clin Cancer Res. 2008. PMID: 18980976
391 results